How would you manage a patient with metastatic NSCLC and high-level MET amplification who achieved a near CR on tepotinib but is unable to tolerate dose-reduced tepotinib?
The patient did not receive immunotherapy initially due to delayed insurance authorization. His performance status is poor, and his main toxicity from tepotinib was grade 3 edema.
Community PollStarted
What would your next treatment option be in the event of intolerable peripheral edema from tepotinib?
10 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Colorado Anschutz Medical Center
Answered on
This is one of the more challenging situations I face in the clinic. Peripheral edema is the most notorious side effect of MET TKIs, with an insidious onset of 6-9 weeks after initiation of therapies like capmatinib or tepotinib [Sakamoto and Patil, PMID 36924573; Lin et al., PMID 40386723]. You hav...
Join for free or sign in to see the full answer